Ovarian cancer vaccine trial aims to keep tumors at bay
NCT ID NCT02346747
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized immunotherapy called Vigil in 92 women with advanced ovarian cancer who are currently cancer-free after surgery and chemotherapy. The treatment uses the patient's own tumor cells to create a vaccine that trains the immune system to fight any remaining cancer cells. The main goal is to see if Vigil can delay the cancer from coming back compared to a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMD Asplundh Cancer Pavilion
Abington, Pennsylvania, 19001, United States
-
Barrett Cancer Center University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
Billings Clinic
Billings, Montana, 59101, United States
-
Cancer Care Northwest
Spokane, Washington, 99216, United States
-
Dana Farber Cancer Institute: Gynecologic Oncology
Boston, Massachusetts, 02215, United States
-
Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756, United States
-
Duke University Medical Center, Department of Medicine - Oncology
Durham, North Carolina, 27710, United States
-
Florida Cancer Specialists
West Palm Beach, Florida, 33401, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Franciscan Research Center
Tacoma, Washington, 98405, United States
-
Georgia Cancer Center at Augusta University
Augusta, Georgia, 30912, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Maine Medical Center: MMP Women's Health
Scarborough, Maine, 04074, United States
-
Mary Crowley Cancer Research Centers
Dallas, Texas, 75230, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Nebraska Methodist Hospital
Omaha, Nebraska, 68114, United States
-
Palo Alto Foundation Medical Group
San Francisco, California, 94115, United States
-
Prisma Health Cancer Institute
Greenville, South Carolina, 29605, United States
-
Southern California Permanente Medical Group
Irvine, California, 92618, United States
-
St. Luke's Health Network
Bethlehem, Pennsylvania, 18015, United States
-
Stephenson Cancer Center at University of Oklahoma
Oklahoma City, Oklahoma, 73104, United States
-
University Of Kentucky Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University Of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106, United States
-
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, 36604, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390-9032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- Can a cancer pill keep working outside the lab? a Real-World test begins
- Can a Patient's own immune cells be supercharged to fight ovarian cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?